Garcia et al. (11) suggested that FHS may lead to impaired IGF-1 signaling and affect height because of the difference between the growth response to rhGH and serum IGF-1 (at the upper limit of normal levels during treatment). This evidence concerns the gene IGF1 and Floating-Harbor syndrome.